HALO
Halozyme Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$110.29
−0.42%Year over year
Reported trailing growth
- Revenue
- +41.2%
- EBITDA
- -9.8%
- EBIT
- +38.4%
- EPS
- -21.4%
- Free cash flow
- +49.1%
- Operating cash flow
- +49.4%
Forward estimates
Based on analyst estimates
- Revenue
- +21.4%
- EBITDA
- +115.8%
- EPS
- +171.4%
Three-year CAGR
- Revenue
- +28.4%
- EBITDA
- +22.0%
- EBIT
- +45.0%
- Net income
- +16.2%
- EPS
- +21.3%
- Free cash flow
- +39.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026